Press Release

OWL Metabolomics Announces Scientific and Commercial Participation at International Liver Congress™ / EASL in Vienna

(**Bilbao, Spain**, March 27, 2019) OWL Metabolomics will repeat its involvement in the upcoming EASL Annual Meeting / European Association for the Study of the Liver in conjunction with the International Liver Congress ™ next month.

This year, OWL will be involved as a Scientific Contributor and as a commercial co-sponsor with a booth presence in the "Biotech Village" at the ILC / EASL in Vienna from April 11-13.

OWL's scientific participation will include the presentation of recent metabolomics-based liver research findings in poster sessions, as described below:

- **FRI-289.** Effect of MSDC-0602K treatment on the metabolome of a diet-induced murine model
  Session: NAFLD: Experimental and pathophysiology; 12 April 2019 09:00 - 17:00.

- **SAT-346.** Icosabutate induces a potent reduction in hepatic oxidative stress in rodent models of metabolic stress and fibrosing NASH
  Session: NAFLD: Therapy; 13 April 2019 09:00 - 17:00.

- **SAT-354.** Aramchol, SCD1 inhibitor, improves liver glucose homeostasis in NASH
  Session: NAFLD: Therapy; 13 April 2019 09:00 - 17:00.

- **SAT-425.** Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis
  Session: Non-invasive assessment of liver disease except NAFLD; 13 April 2019 09:00 - 17:00.

- **LBP-10.** A structurally engineered fatty acid, icosabutate, rapidly normalises elevated plasma ALT and gamma-glutamyl transferase (GGT) concentrations in a study population at high risk of NAFLD/NASH
  Late breaker poster session: General hepatology. Dates: April 11-13, 9:00 AM-5:00 PM.

OWL's commercial participation will include an industry booth in the Biotech Village area of the Congress Hall (Booth # BV3). The OWL staff welcome your visit to our booth and suggest that a time be reserved for a brief discussion during the standard booth hours of 9:00 – 17:00 daily from April 11-13.

Please contact the OWL Meeting Administrator, Nerea San Juan, (nsanjuan@owlmetabolomics.com), to help identify a meeting time with our staff.

OWL's long-standing focus on fatty liver disease progression, diagnosis

OWL Metabolomics collaborates with numerous NASH pharma and biotech research organizations throughout the world in the liver space by constructing unique metabolomics-based analyses to determine specific changes in disease status and changes in disease severity within a variety of fatty liver patient types.

OWL has been involved in active NASH-related metabolomic research for over 15 years, including metabolomics-based pre-clinical analysis in early-candidate drug studies, verification of treatment-arm parity at baseline, active human trial monitoring (i.e., surrogate marker of drug effect, monitoring of therapeutic impact / dose effects), and the development of tailored companion diagnostics to more accurately predict likely patient responders to a given drug treatment.

In addition to the detailed NASH research collaborations with pharma, OWL Metabolomics has produced and validated the OWLiver® tests, a set of serum-based diagnostic assays for determining the presence of NASH (non-alcoholic steatohepatitis) versus NAFL (non-alcoholic fatty liver) and normal (healthy) liver in suspected patients, with a primary goal of reducing the need for more invasive or more expensive testing modalities, including the invasive liver biopsy. Today's international 'gold-standard' for the definitive diagnosis of NASH remains a cumbersome and expensive invasive tissue biopsy procedure. The key benefit of such blood-based advanced testing is that it can be performed safely at fairly frequent intervals at any time or any location where the patient undergoes a standard blood draw in the clinic.

History of OWL Metabolomics

OWL Metabolomics is a global metabolomics service provider to the pharma industry with a main focus supporting clinical trials in liver diseases and other prevalent human diseases as well as research in indications where metabolomic plays a key role, including drug therapy monitoring and biomarker discovery.

OWL Metabolomics is also committed to the identification, validation and global commercialization of novel diagnostic assays for liver diseases. Since its inception in 2002, OWL Metabolomics has pioneered unique diagnostic research within the fatty liver space, a field of considerable focus in NASH drug development.

More information: http://www.owlmetabolomics.com/
LinkedIn®: owlmetabolomics